Melqart
TERN · Medicine & biotech

Terns Pharmaceuticals

Develops a pill to treat leukemia, a type of blood cancer.
Sold all
Melqart sold all 507,187 of its Terns Pharmaceuticals shares between April and June. On March 31, 2026, they were worth about $27 million.
Mar 31
507,187
Jun 30
None

The numbers

Shares they used to own
507,187
Shares now
0
Value on Mar 31, 2026
$26,738,899
about $27 million
Kind
Shares
Owned by
None of the funds we follow
More about Terns Pharmaceuticals
The value uses the price on Mar 31, 2026. They may have sold at a different price.
See the original filing on SEC.gov
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works